Effect of supplementation in treatment of women with polycystic ovary syndrome
Phase 3
Completed
- Conditions
- Polycystic ovarian syndrome.Polycystic ovarian syndromeE28.2
- Registration Number
- IRCT201704245623N114
- Lead Sponsor
- Vice chancellor for research, Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Patients with PCOS according to Rotterdam criteria
Aged 18 to 40 years
Written informed consent
Exclusion Criteria
Pregnancy
Adrenal hyperplasia
Androgen secreting tumors
Hyperprolactinemia
Thyroid dysfunction
Diabetes or impaired glucose tolerance
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total testosterone. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does combined omega-3 and vitamin D supplementation modulate insulin resistance and lipid metabolism in PCOS patients (NCT ID: IRCT201704245623N114)?
What is the comparative effectiveness of omega-3 and vitamin D versus standard-of-care treatments for metabolic abnormalities in PCOS?
Which biomarkers predict metabolic response to combined omega-3 and vitamin D supplementation in PCOS patients?
What are the safety profiles and adverse event management strategies for omega-3 and vitamin D supplementation in PCOS trials?
Are there synergistic effects of omega-3 and vitamin D with other nutraceuticals in improving PCOS-related metabolic outcomes?